The Gori Law Firm
Get Your FREE Case Review 24 Hours A Day
To protect your safety during the coronavirus (COVID-19) crisis, we offer telephone and video conferences, in addition to face-to-face meetings. Please contact our office today to set up a remote consultation.
Arrow
Mesothelioma
& Asbestos
Mesothelioma
& Asbestos

Learn more about mesothelioma, symptoms & treatment, frequently asked questions and more.
Arrow
Mesothelioma
& Asbestos
Mesothelioma
& Asbestos

Learn more about mesothelioma, symptoms & treatment, frequently asked questions and more.
Arrow
Mass Torts, Defective Drugs & Products
Mass Torts, Defective Drugs & Products
We help victims of dangerous drugs (Actos, Mirena, Lipitor, etc.) and faulty devices (hip implants, pacemakers, etc.)
Arrow
Mass Torts, Defective Drugs & Products
Mass Torts, Defective Drugs & Products
We help victims of dangerous drugs (Actos, Mirena, Lipitor, etc.) and faulty devices (hip implants, pacemakers, etc.)
Arrow
Personal Injury &
Workers' Compensation
Personal Injury &
Workers' Compensation

We help clients who need assistance with work-related injuries linked to asbestos and other serious problems.
Arrow
Personal Injury &
Workers' Compensation
Personal Injury &
Workers' Compensation

We help clients who need assistance with work-related injuries linked to asbestos and other serious problems.

Are genetic biomarkers the key to treating mesothelioma?

On Behalf of | May 30, 2017 | Blog |

Victims of malignant mesothelioma — an aggressive form of cancer typically linked to asbestos exposure — have few effective treatment options available today. In fact, while overall survival periods have increased in recent years due to the introduction of chemotherapy treatments, some estimates still put the average survival at only 14.5 months. Even worse, the response rate to chemotherapy when it comes to malignant mesothelioma is only roughly 40 percent. However, researchers in Slovenia have developed a model that will hopefully improve these numbers. Specifically, they recently studied whether genetic biomarkers can be used to create individualized treatment options for mesothelioma victims, which they hope will improve the response rate to chemotherapy.

Why biomarkers?

Doctors and researchers have long known that there is no one-size-fits-all treatment when it comes to cancer. Therefore, researchers involved in the Slovenian study — which was recently published in the online journal Scientific Reports and made available on the National Center for Biotechnology Information (NCBI) website — decided to see if they could develop an algorithm that would help determine the best treatment option for any given patient given certain biomarkers.

As part of this study, they genotyped 189 malignant mesothelioma patients, with each patient receiving a chemotherapy treatment of either gemcitabine/cisplatin or pemetrexed/cisplatin.

Based on the data they collected during the study, the researchers ultimately concluded that “effective chemotherapy could be recommended for 85.5 [percent]” of malignant mesothelioma victims by simply using the proposed algorithm developed by the researchers.

However, while this conclusion is certainly good news for victims of mesothelioma and asbestos, the researchers clearly stated that their findings still need to be confirmed in a prospective study.

Mesothelioma Lawyers and Personal Injury Attorneys

Get a Free Case Review!

Archives

FindLaw Network